Outcome of COVID-19 in allogeneic stem cell transplant recipients : Results from the EPICOVIDEHA registry
Busca, Alessandro (AOU Città della Salute e della Scienza di Torino)
Salmanton-García, Jon (University of Cologne)
Marchesi, Francesco (IRCCS Regina Elena National Cancer Institute)
Farina, Francesca (IRCCS Ospedale San Raffaele (Milà, Itàlia))
Cengiz Seval, Guldane (Ankara University)
van Doesum, Jaap A. (University Medical Center Groningen)
De Jonge, Nick (Amsterdam University Medical Center (UMC))
Bahr, Nathan C. (University of Kansas Medical Center)
Maertens, Johan (KU Leuven. Department of Hematology)
Meletiadis, Joseph (University General Hospital Attikon (Haidari, Grècia))
Fracchiolla, Nicola (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milà, Itàlia))
Weinbergerová, Barbora (Department of Internal Medicine - Hematology and Oncology, Masaryk University Hospital Brno)
Verga, Luisa (Università Milano-Bicocca)
Ráčil, Zdeněk (Institute of Hematology and Blood Transfusion)
Jiménez, Moraima (Universitat Autònoma de Barcelona. Departament de Medicina)
Glenthøj, Andreas (Copenhagen University Hospital)
Blennow, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia))
Tanase, Alina Daniela (University of Medicine and Pharmacy Carol Davila)
Schönlein, Martin (University Medical Center Hamburg-Eppendorf. Department of Oncology, Hematology and Bone Marrow Transplantation)
Prezioso, Lucia (University Hospital of Parma (Parma, Itàlia))
Khanna, Nina (University Hospital Basel (Basilea, Suïssa))
Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Žák, Pavel (University Hospital Hradec Kralove (República Txeca))
Nucci, Marcio (Universidade Federal do Rio de Janeiro)
Machado, Marina (Hospital General Universitario Gregorio Marañón)
Kulasekararaj, Austin (King's College London)
Espigado, Ildefonso (Instituto de Biomedicina de Sevilla)
De Kort, Elizabeth (Radboud University Medical Center)
Ribera-Santa Susana, José-María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Marchetti, Monia (Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo)
Magliano, Gabriele (ASST Grande Ospedale Metropolitano Niguarda)
Falces-Romero, Iker (Hospital Universitario La Paz (Madrid))
Ilhan, Osman (Ankara University)
Ammatuna, Emanuele (University Medical Center Groningen)
Zompi, Sofia (AOU Città della Salute e della Scienza di Torino)
Tsirigotis, Panagiotis (University General Hospital Attikon (Haidari, Grècia))
Antoniadou, Anastasia (University General Hospital Attikon (Haidari, Grècia))
Zambrotta, Giovanni (Università Milano-Bicocca)
Nordlander, Anna (Karolinska University Hospital and Karolinska Institutet (Suècia))
Karlsson, Linda Katharina (University of Copenhagen)
Hanakova, Michaela (Institute of Hematology and Blood Transfusion)
Dragonetti, Giulia (Fondazione Policlinico Universitario Agostino Gemelli - IRCCS)
Cabirta, Alba (Vall d'Hebron Institut d'Oncologia)
Berg Venemyr, Caroline (Copenhagen University Hospital - Rigshospitalet)
Gräfe, Stefanie K. (University of Cologne)
Van Praet, Jens (AZ Sint-Jan Brugge-Oostende AV. Department of Nephrology and Infectious diseases)
Tragiannidis, Athanasios (Aristotle University of Thessaloniki)
Petzer, Verena (Medical University of Innsbruck. Department of Hematology and Oncology)
López García, Alberto (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Itri, Federico (San Luigi Gonzaga Hospital - Orbassano)
Groh, Ana (Infektiologie, Universitätsklinikum Frankfurt am Main)
Gavriilaki, Eleni (George Papanicolaou General Hospital (Tessalònica, Grècia))
Dargenio, Michelina (Ospedale Vito Fazzi (Lecce, Itàlia))
Rahimli, Laman (University of Cologne)
Cornely, Oliver A. (German Centre for Infection Research (DZIF))
Pagano, Livio (Università Cattolica del Sacro Cuore)

Data:	2023
Resum:	The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. This multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Allogeneic HSCT ; COVID-19 infection ; Immunocompromised patients ; SARS-CoV-2 ; Hematological malignances
Publicat a:	Frontiers in immunology, Vol. 14 (february 2023) , ISSN 1664-3224

DOI: 10.3389/fimmu.2023.1125030
PMID: 36911708

9 p, 1.5 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats